Agios says mitapivat Phase 3 RISE UP trial boosts hemoglobin in sickle cell disease

• Agios flagged new mitapivat data across multiple rare hemolytic anemias scheduled for presentation at European Hematology Association Congress 2026 in Stockholm on June 11-14.
• Key Phase 3 RISE UP sickle cell disease readout, set for a June 13 plenary session, showed patients on mitapivat were more likely to achieve meaningful improvement in anemia with a safety profile consistent with prior experience.
• Phase 3 ENERGIZE long-term thalassemia update, due June 13, indicated benefits were sustained over extended treatment, with additional patients improving after switching from placebo or continuing therapy.
• Phase 2 SATISFY follow-up, slated for June 11, pointed to sustained anemia improvement in select rare hemolytic anemias, with signals of reduced downstream disease burden in responders.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agios Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605120930PRIMZONEFULLFEED9718043) on May 12, 2026, and is solely responsible for the information contained therein.